Ocular flutter as the first sign of a breast carcinoma

Chlara Maes, Hilde Janssens, Lies Goovaerts, Maria Dieltiens, Maarten Schrooten, Catherine Cassiman

ABSTRACT

Introduction: Ocular flutter is a rare ophthalmic finding and can be the presenting sign of potentially serious disease. The most common etiology is a paraneoplastic disorder and therefore, a workup for a malignancy should always be initiated. Case Report: We present a case of a 48-year-old female who presented with a two-month history of progressive anorexia, wasting, vomiting and vertigo and recently associated complaints of diplopia and blurred vision. Ophthalmic examination revealed horizontal saccadic intrusions, consistent with ocular flutter. Further extensive workup revealed an adenocarcinoma of the right breast. Immunologic testing showed positive anti-Ri antibodies which are reported to be associated with breast carcinomas and a paraneoplastic syndrome. The patient underwent local excision and adjuvant chemotherapy, radiotherapy and hormonal therapy were administered. The clinical picture deteriorated rapidly to an overt opsoclonus and a gait disorder. Six months after the initial presentation, she became symptom free. Conclusion: Ocular flutter is an alarming finding and should always alert the clinician to screen for a potential underlying malignancy.

Keywords: Anti-Ri, Breast carcinoma, Ocular flutter, Opsoclonus, Paraneoplastic syndrome

INTRODUCTION

Ocular flutter is a rare oculomotor syndrome and is characterized by horizontal back to back saccades without intersaccadic interval [1]. Opsoclonus shares some of the same properties, but consists of multidirectional saccades. Both can be considered as a part of one spectrum [1]. The most frequent etiology is a paraneoplastic syndrome [2]. Ocular flutter and opsoclonus are always alarming findings and should be recognized in clinical practice as soon as possible [2]. Tumors most frequently associated are lung and breast carcinoma [2, 3]. Prompt further investigations, screening for those potential malignacies, should be initiated as soon as possible [4]. Antibodies most frequently associated with breast cancer associated opsoclonus-myoclonus syndrome are anti-Ri antibodies, however...
they are of limited diagnostic value because most patients are seronegative [5, 6]. We present a case of a 48-year old woman who presented with ocular flutter as the initial sign of an underlying breast carcinoma and who recovered completely after treatment.

CASE REPORT

A 48-year old female presented to the department of ophthalmology of our hospital because of disabling complaints of diplopia and blurred vision. She had a two-month history of progressive anorexia, wasting, vomiting and vertigo. She was diagnosed with esophagitis and potential benign paroxysmal positional vertigo during a recent hospitalization. At the initial examination her visual acuity was 20/20 in both eyes. Ocular motility examination revealed intermittent bursts of high-frequency horizontal saccades without an intersaccadic interval, consistent with ocular flutter. Eye movements were full range in all directions and there was a small concomitant esodeviation. Her medical history was unremarkable, except for hypercholesterolemia. She was taking a statin and a proton pump inhibitor and recently cinnarizine, alizapride, trazodone and alprazolam were associated because of her progressive symptoms of anorexia and vertigo, without relief of symptoms. She denied any use of alcohol or drugs. Two weeks before the start of her complaints, she suffered an aspecific infectious episode.

The patient was referred to the department of neurology for urgent further investigation. She was admitted to the emergency department because of significant progression of the ocular flutter with secondary severe visual blur and an unstable gait. Neurologic clinical examination showed brisk osteotendinous reflexes without pathological reflexes and a broad-based ataxic gait. Swallowing was uncoordinated. Video-oculogram confirmed the diagnosis of ocular flutter (Video 1). General biochemical blood tests were normal and screening for (post)infectious disease was negative. Anti-neuronal antibody testing (anti-Hu, anti-Ri, anti-Yo, anti-Ma2, etc.) was positive for anti-Ri-antibodies. Her cerebrospinal fluid (CSF) showed a lymphocytic pleocytosis (8.4/µL; normal <5.0/µL) and twelve oligoclonal bands. Brain MRI scan was normal. Screening with mammography revealed a hypoechoic lesion (2.2x1.8x2.0 cm) in the right breast (Figure 1). Core biopsy was suggestive of a moderately differentiated invasive ductal adenocarcinoma. She underwent wide local excision and sentinel node biopsy. Histologic examination confirmed a grade 2 moderately differentiated invasive ductal adenocarcinoma (Figure 2). Three sentinel nodes were negative. Final staging was pT2N0M0. Adjuvant treatment with chemotherapy (4 cycles of epirubicin and cyclophosphamide followed by 12 cycles of taxotere), radiotherapy and hormonal therapy (tamoxifen) was initiated. Immunotherapy treatment with plasmapheresis, steroids and azathioprine were successively started because the ocular flutter was severely disabling.

Gabapentin and clonazepam were also tried in association. Despite treatment, there was initial progression of the clinical image. The eye movements evolved into an overt opsoclonus (Video 2) with multidirectional saccades. She continued to experience severe oscillopsia, making her functionally blind with a binocular visual acuity of 20/200. The ataxia progressed to an incapability to walk and made here wheelchair dependent. She mentioned infrequent shock-like movements of arms and head, reminiscent of myoclonus. Six months after the initial presentation, contemporaneously with the chemotherapy, her symptoms disappeared slowly and in two months she recovered completely.


Figure 1: Mammography demonstrating a hypo-echogenic lesion (2.2x1.8x2.0 cm) in the right breast.
became completely symptom free, apart from a mild peripheral neuropathy, likely treatment induced.

**DISCUSSION**

Ocular flutter is part of the spectrum of saccadic intrusions without intersaccadic interval. It consists of back-to-back saccades in the horizontal plane. Opsoclonus shares some of the same properties, but consists of multidirectional saccades. It usually occurs in association with myoclonus and ataxia [1]. They both can be considered as part of one spectrum with the same etiology, pathophysiology and clinical implications [1]. Ocular flutter and opsoclonus are always alarming findings and require prompt further investigation. The most common etiology in adults is a paraneoplastic syndrome [2]. In our case, the presenting sign of ocular flutter heralded the diagnosis of a breast carcinoma which, together with lung tumors, is most frequently associated with a paraneoplastic syndrome [2]. In children, neuroblastoma has to be ruled out [2, 3]. The exact pathophysiology remains unknown, but the underlying mechanism is presumed to be an auto-immune mediated response. Cerebrospinal fluid analysis may show pleocytosis and protein elevation, as in our case [3, 4]. Auto-antibodies may be detected in a small percentage of cases, but are of limited diagnostic value because most patients are seronegative [3–5]. A recent review showed that onconeural antibodies were positive in only 11% of cases [6]. In our case, anti-Ri antibodies were positive. They are associated with opsoclonus-myoclonus syndrome and are reported to be associated with gynecological and small cell lung cancer, but are mostly associated with breast carcinoma [5]. Symptoms associated with this syndrome are frequently very disabling and may sometimes precede the diagnosis for several months or years [5]. Most frequent initial symptoms include acute vertigo, nausea and vomiting, gait instability and vision abnormalities [6, 7]. The primary treatment should always consist of treating the underlying malignancy as soon as possible. Further treatment options include immunosuppressive therapies such as corticosteroids, azathioprine and plasmapheresis [2, 4, 5]. Also anticonvulsants have proven to be effective [2, 4, 5]. In general, paraneoplastic ocular flutter and opsoclonus have a more severe course than the idiopathic form and the majority of patients recover only partially [3, 6, 7, 8]. Evolution into severe encephalopathy and coma can occur if immunotherapy is not associated with primary tumor treatment [3, 6–8]. In our case, the patient did not respond to immunosuppressive or supportive medical treatment and there was initially progression of the clinical image. Eventually, after the initiation of chemotherapy complete regression of the ocular flutter and ataxia were established despite a mild peripheral neuropathy.

**CONCLUSION**

We report a case of ocular flutter as the presenting sign of a breast carcinoma. Ocular flutter is a rare, but alarming finding and should alert the clinician to screen for a potential underlying malignancy.

*********

**Acknowledgement**

We would like to acknowledge the contribution of Dr. Frederik Deman, Department of Pathology University Hospitals Leuven, for providing histology images.

**Author Contributions**

Chlara Maes – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Hilde Janssens – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Lies Goovaerts – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Maria Dieltiens – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Maarten Schrooten – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
it critically for important intellectual content, Final approval of the version to be published
Catherine Cassiman – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor
The corresponding author is the guarantor of submission.

Conflict of Interest
Authors declare no conflict of interest.

Copyright
© 2017 Chlara Maes et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

REFERENCES